Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT05578209
Active, not recruiting Not applicable

Therapeutic Impacts of Theta Burst Stimulation Over Bilateral Posterior Superior Temporal Sulcus in Autism Spectrum Disorder

NCT05578209 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Chang Gung Memorial Hospital
Phase
Not applicable
Started
2023-02-03
Last updated
2025-06-04

Condition(s) studied

Autism Spectrum Disorder

Investigational drug(s) / intervention(s)

intermittent theta burst stimulation

intermittent theta burst stimulation: stimulatory protocol

Study summary

The investigator would like to investigate the impact of intermittent theta burst stimulation over bilateral posterior superior temporal sulcus in autism spectrum disorder

Eligibility

Sex
ALL
Min age
8 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria: * Autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule II (CSS≧6) * No change in psychiatric drugs within one month Exclusion Criteria: * Previous or current severe neurological disorder such as epilepsy, visual or hearing impairment * Previous or current severe systemic disease such as cardiovascular disease, diabetes or infection * Previous or current severe brain injury * Implementation of metal materials such as pacemaker or medication pump * Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse * Pregnancy * Individuals with a significant brain abnormality such as intracranial space occupied lesions * History of brain surgery or nervous system infection, such as meningitis and encephalitis * Previous febrile seizures * Concurrent use of medications which increased the risk of seizure attack. * Participate another clinical trial within one month. * Unable to complete MRI scan (claustrophobia) * Skin trauma on application site * Individuals with a large ischemic scar * Individuals suffering from multiple sclerosis * Individuals suffering from sleep deprivation during rTMS procedures * Individuals with a heavy consumption of alcohol * Individuals with a migraine headache from increased intracranial pressure

Primary outcome measure(s)

  • Changes of total scores of Social Responsiveness Scale — baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)
    Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.
  • Changes of total scores of Repetitive Behavior Scale-Revised — baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)
    Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.

Trial sites (1)

FacilityCityRegionStatus
Chang Gung Memorial Hospital Taoyuan Taiwan

More Chang Gung Memorial Hospital trials in Taiwan

Frailty Assessment and Intervention in Elderly Patients with Gastric Cancer Receiving Gastrectomy and Adjuvant Chemotherapy Recruiting
Comparison Between Combined ALLR With Single Bundle and Double Bundle Anterior Cruciate Ligament Reconstruction Recruiting
Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer Starting soon
A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia Starting soon
Buccal Prosthetic Contour Angles and Peri-Implant Tissue Changes Around Dental Implants Active, not recruiting

Other trials for the same condition

Explore the Impacts of One Session and Multiple Session Theta Burst Stimulation Over Cerebellum in Adults With Autism Spectrum Disorder Recruiting
Exploring the Gut-Brain-Behavior Axis With Biomarkers, Probiotic Efficacy, and Artificial Intelligence Algorithms Recruiting
Social Robots and Board Games for Children With Autism Spectrum Disorder Recruiting
Explore the Therapeutic Effect of Theta Burst Stimulation on Emotion Regulation in Autism With Minimally Verbal Ability or Intellectual Disability Recruiting
Medial Prefrontal Cortex Brain Magnetic Stimulation in Autism Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05578209 on ClinicalTrials.gov ↗ ← All trials in Taiwan